Achieve Life Sciences Inc ACHV
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1995-10-12 |
| Shares Out. | 102,660,000 |
| Website | achievelifesciences.com/ ↗ |
| Phone | 13026365400 |
| Employees | 28 |
| Net Income | -$10.2M |
| Free Cash Flow | -$45.3M |
| Total Assets | $33.1M |
| Total Liabilities | $22.4M |
| Equity | $10.7M |
About Achieve Life Sciences Inc
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Achieve Life Sciences Inc is a publicly traded company under the ticker symbol ACHV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)